(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)biphenyl-3-yl)methoxy)-2,3-dihydro-1-benzofuran-3-yl)acetic acid hemihydrate,
fasiglifam,
TAK-875,
TAK-875,
Fasiglifam,
1000413-72-8,
TAK875,
TAK 875,
UNII-GLP1W4JXAH,
GLP1W4JXAH,
(S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid,
CHEMBL1829174,
[(3s)-6-({2',6'-Dimethyl-4'-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid,
3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-,
J-501277,
(3S)-6-[[2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid,
[(3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid,
Fasiglifam [USAN:INN],
4phu,
((3S)-6-((3-(4-(3-Methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl)acetic acid,
[(3S)-6-([2',6'-DIMETHYL-4'-[3-(METHYLSULFONYL)PROPOXY]BIPHENYL-3-YL]METHOXY)-2,3-DIHYDRO-1-BENZOFURAN-3-YL]ACETIC ACID,
Fasiglifam (INN),
PubChem24441,
TAK-875(Fasiglifam),
cc-64,
SCHEMBL204652,
GTPL6484,
C29H32O7S,
KS-00001CRE,
AOB2992,
EX-A203,
QCR-231,
BZCALJIHZVNMGJ-HSZRJFAPSA-N,
1234474-57-7,
BCP02430,
ABP000968,
BDBM50386790,
MFCD18251445,
ZINC68208039,
AKOS025289552,
CS-0282,
DB12491,
PB24359,
RL00005,
RL00413,
NCGC00346669-01,
AC-25651,
AK170559,
AT-35664,
HY-10480,
SC-86271,
AB0033816,
A8339,
X7587,
D10336,
Q-4156,
1000413-72-8 , TAK875 , TAK 875,
2-[(3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid,
2YB,
Fasiglifam [INN],
D0V1WQ,
CHEMBL2047159,
ACN-037499,
A11018,
C557331,
(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)biphenyl-3-yl)methoxy)-2,3-dihydro-1-benzofuran-3-yl)acetic acid hemihydrate,
109635-64-5,